FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2763185726> ?p ?o ?g. }

• W2763185726 endingPage "103116" @default.
• W2763185726 startingPage "103108" @default.
• W2763185726 abstract "// Hojjat Ahmadzadehfar 1, * , Stephan Schlolaut 1, * , Rolf Fimmers 2 , Anna Yordanova 1 , Stefan Hirzebruch 1 , Carl Schlenkhoff 1 , Florian C. Gaertner 1 , Zool Hilmi Awang 1 , Stefan Hauser 3 and Markus Essler 1 1 Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany 2 Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Germany 3 Department of Urology, University Hospital Bonn, Bonn, Germany * These authors contributed equally to this work Correspondence to: Hojjat Ahmadzadehfar, email: hojjat.ahmadzadehfar@ukb.uni-bonn.de Keywords: 177 Lu, overall survival, PSMA, radioligand therapy, prostate cancer Received: August 25, 2017      Accepted: October 04, 2017      Published: October 07, 2017 ABSTRACT Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis of and therapy for metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to measure overall-survival (OS) in mCRPC patients who received either abiraterone or enzalutamide prior to PSMA therapy. The second aim of this study was to analyse the predictors of OS according to different pre-therapeutic parameters and also the responses to the first cycle of radioligand therapy (RLT) base on PSA level. Patients with mCRPC and a history of therapy with either abiraterone or enzalutamide or both, were included in this study. Different laboratory tests and pre-therapeutic parameters have been included into the analysis. One-hundred patients received a total of 347 cycles of Lu-PSMA (median: three cycles). 69 patients showed a decline in PSA two months after the first cycle, and 38 of those patients showed a PSA decline of = > 50%. The median OS was 60 weeks. In the multivariate analysis, the level of albumin, AST and haemoglobin, existence of liver metastases and a decline of > 14% in PSA level had a significant impact on overall-survival. The median OS is significantly longer in patients without hepatic involvement, with high levels of albumin and Hb and low levels of AST. A decline in PSA levels of more than 14% was the most important response parameter with regard to overall survival." @default.
• W2763185726 created "2017-10-20" @default.
• W2763185726 creator A5003820676 @default.
• W2763185726 creator A5024581793 @default.
• W2763185726 creator A5030999156 @default.
• W2763185726 creator A5031860720 @default.
• W2763185726 creator A5038437811 @default.
• W2763185726 creator A5042204788 @default.
• W2763185726 creator A5077069685 @default.
• W2763185726 creator A5083642995 @default.
• W2763185726 creator A5087475741 @default.
• W2763185726 creator A5088399737 @default.
• W2763185726 date "2017-10-07" @default.
• W2763185726 modified "2023-09-24" @default.
• W2763185726 title "Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy" @default.
• W2763185726 cites W1546799663 @default.
• W2763185726 cites W1788773500 @default.
• W2763185726 cites W1973942000 @default.
• W2763185726 cites W2038750132 @default.
• W2763185726 cites W2055346449 @default.
• W2763185726 cites W2080439368 @default.
• W2763185726 cites W2141454098 @default.
• W2763185726 cites W2148643283 @default.
• W2763185726 cites W2278392405 @default.
• W2763185726 cites W2299859133 @default.
• W2763185726 cites W2302508993 @default.
• W2763185726 cites W2304896218 @default.
• W2763185726 cites W2313876620 @default.
• W2763185726 cites W2315998085 @default.
• W2763185726 cites W2332176343 @default.
• W2763185726 cites W2341926107 @default.
• W2763185726 cites W2511755939 @default.
• W2763185726 cites W2515351720 @default.
• W2763185726 cites W2517230528 @default.
• W2763185726 cites W2520024435 @default.
• W2763185726 cites W2522755457 @default.
• W2763185726 cites W2525124727 @default.
• W2763185726 cites W2532226140 @default.
• W2763185726 cites W2589729932 @default.
• W2763185726 cites W2599305587 @default.
• W2763185726 cites W2612027160 @default.
• W2763185726 cites W2625296464 @default.
• W2763185726 cites W2728713011 @default.
• W2763185726 doi "https://doi.org/10.18632/oncotarget.21600" @default.
• W2763185726 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5732715" @default.
• W2763185726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29262549" @default.
• W2763185726 hasPublicationYear "2017" @default.
• W2763185726 type Work @default.
• W2763185726 sameAs 2763185726 @default.
• W2763185726 citedByCount "66" @default.
• W2763185726 countsByYear W27631857262018 @default.
• W2763185726 countsByYear W27631857262019 @default.
• W2763185726 countsByYear W27631857262020 @default.
• W2763185726 countsByYear W27631857262021 @default.
• W2763185726 countsByYear W27631857262022 @default.
• W2763185726 countsByYear W27631857262023 @default.
• W2763185726 crossrefType "journal-article" @default.
• W2763185726 hasAuthorship W2763185726A5003820676 @default.
• W2763185726 hasAuthorship W2763185726A5024581793 @default.
• W2763185726 hasAuthorship W2763185726A5030999156 @default.
• W2763185726 hasAuthorship W2763185726A5031860720 @default.
• W2763185726 hasAuthorship W2763185726A5038437811 @default.
• W2763185726 hasAuthorship W2763185726A5042204788 @default.
• W2763185726 hasAuthorship W2763185726A5077069685 @default.
• W2763185726 hasAuthorship W2763185726A5083642995 @default.
• W2763185726 hasAuthorship W2763185726A5087475741 @default.
• W2763185726 hasAuthorship W2763185726A5088399737 @default.
• W2763185726 hasBestOaLocation W27631857261 @default.
• W2763185726 hasConcept C121608353 @default.
• W2763185726 hasConcept C126322002 @default.
• W2763185726 hasConcept C143998085 @default.
• W2763185726 hasConcept C170493617 @default.
• W2763185726 hasConcept C2775832370 @default.
• W2763185726 hasConcept C2776421732 @default.
• W2763185726 hasConcept C2776551883 @default.
• W2763185726 hasConcept C2777899217 @default.
• W2763185726 hasConcept C2780192828 @default.
• W2763185726 hasConcept C2993559085 @default.
• W2763185726 hasConcept C61367390 @default.
• W2763185726 hasConcept C67847695 @default.
• W2763185726 hasConcept C71924100 @default.
• W2763185726 hasConceptScore W2763185726C121608353 @default.
• W2763185726 hasConceptScore W2763185726C126322002 @default.
• W2763185726 hasConceptScore W2763185726C143998085 @default.
• W2763185726 hasConceptScore W2763185726C170493617 @default.
• W2763185726 hasConceptScore W2763185726C2775832370 @default.
• W2763185726 hasConceptScore W2763185726C2776421732 @default.
• W2763185726 hasConceptScore W2763185726C2776551883 @default.
• W2763185726 hasConceptScore W2763185726C2777899217 @default.
• W2763185726 hasConceptScore W2763185726C2780192828 @default.
• W2763185726 hasConceptScore W2763185726C2993559085 @default.
• W2763185726 hasConceptScore W2763185726C61367390 @default.
• W2763185726 hasConceptScore W2763185726C67847695 @default.
• W2763185726 hasConceptScore W2763185726C71924100 @default.
• W2763185726 hasIssue "61" @default.
• W2763185726 hasLocation W27631857261 @default.
• W2763185726 hasLocation W27631857262 @default.
• W2763185726 hasLocation W27631857263 @default.

• next